[1]程江雪 武旭 郭东艳 史亚军 邹俊波 吴睿彬 张小明.基于网络药理学研究当-归赤芍药对治疗心绞痛作用机制[J].陕西中医药大学学报,2022,(03):097-104.[doi:10.13424/j.cnki.jsctcm.2022.03.023]
点击复制

基于网络药理学研究当-归赤芍药对治疗心绞痛作用机制
分享到:

《陕西中医药大学学报》[ISSN:2096-1340/CN:61-1501/R]

卷:
期数:
2022年03期
页码:
097-104
栏目:
论著
出版日期:
2022-05-26

文章信息/Info

文章编号:
2096-1340(2022)03-0097-08
作者:
程江雪12 武旭1 郭东艳12 史亚军12 邹俊波12 吴睿彬1 张小明1
1.陕西中医药大学药学院,陕西 咸阳 712046;
2.陕西省中药基础与新药研究重点实验室,陕西 咸阳 712046
关键词:
关键词:当归赤芍药对网络药理学心绞痛作用机制
分类号:
R285.5
DOI:
10.13424/j.cnki.jsctcm.2022.03.023
文献标志码:
A
摘要:
摘 要:目的 通过网络药理学的方法研究当归-赤芍药对治疗心绞痛的作用机制。方法 基于TCMSP、GENECARD、DISGENET、TTD、UNIPROT等数据库,筛选出药物以及疾病的靶点基因,使用venny 2.1在线作图平台取其交集,cytoscape3.7.0创建其药物-有效成分-基因-疾病调控网络,借助STRING数据库建立其蛋白互相作用PPI网络进行核心基因的筛选,使用Cytoscape3.7.0相关插件运用R语言进行GO和KEGG富集分析,进一步形成靶点-通路网络图。结果 当归赤芍有效成分共28个,药物疾病交集靶点基因243个,作用于疾病的核心基因是SRC、VEGFA、MAPK3、AKT1、HRAS等。GO分析条目134个,包括内肽酶活性、丝氨酸水解酶活性、丝氨酸型肽酶活性、丝氨酸型内肽酶活性和蛋白酪氨酸激酶活性等。KEGG信号通路146个,包括前列腺癌、表皮生长因子受体酪氨酸激酶抑制剂耐药、补体途径、癌症蛋白聚糖和丝裂原活化蛋白激酶信号通路等。结论 当归-赤芍药对可通过调节SRC、VEGFA、MAPK3等靶点基因,调控前列腺癌、表皮生长因子受体酪氨酸激酶抑制剂耐药、补体途径等实现抗癌、改善血流动力学、促进血管生成,从而发挥治疗心绞痛作用。

参考文献/References:

[1]Fihn SD,Blankenship JC,Alexander KP,et al.2014 acc/aha/aats/pcna/scai/sts focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease:a report of the American college of Cardiology/American heart association task force on practice guidelines,and the American association for thoracic surgery,preventive cardiovascular nurses association,society for cardiovascular angiography and interventions,and society of thoracic surgeons[J].Journal of the American College of Cardiology,2014,64(18):1929-1949.
[2 ]GBD Causes of Death Collaborators.Global,regional,and national age-sex-specific mortality for 282 causes of death in 195 countries and territories,1980-2017:a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet (London,England),2018,392(10159):1736-1788.
[3]Morishita T,Uzui H,Nakano A,et al.Association of plasma pentraxin-3 levels with coronary risk factors and the lipid profile:a cross-sectional study in Japanese patients with stable angina pectoris[J].Heart and Vessels,2018,33(11):1301-1310.
[4]卢红蓉,杜松.冠心病病因病机理论研究概述[J].环球中医药,2015,8(2):186-189.
[5]李婵玉,李耀兵,王洪浩,等.冠心病气虚血瘀证的临床研究进展[J].新疆中医药,2019,37(6):118-121.
[6]邹文娟.从《伤寒论》论冠心病心绞痛发病机理与防治[J].四川中医,2020,38(5):42-44.
[7]党林林,张瑞芬.运用施今墨强心止痛对药治疗冠心病心绞痛的机理探析[J].内蒙古中医药,2021,40(4):146-148.
[8]周广社.加味四妙勇安汤治疗热毒血瘀型心绞痛45例[J].陕西中医,2009,30(10):1287-1288.
[9]杨威,张学进,郭勇.热毒血瘀证与炎症相关性研究进展[J].中华中医药学刊,2010,28(10):2168-2171.
[10]张健荣,李民,孙学娟.温病热毒血瘀证证型治法探析[J].中医研究,2013,26(11):8-12.
[11]赵庭勇.温病热毒血瘀证证治浅探[J].湖北中医杂志,2010,32(6):58-59.
[12]陈可冀.血瘀证与活血化瘀治疗临床研究[C]//第六次全国中西医结合血瘀证及活血化瘀研究学术大会论文集.延吉,2005:16-19.
[13]程江雪.中药提取物组合物的专利信息分析及专利保护研究[D].北京:北京中医药大学,2016.
[14]程江雪,唐志书,郭东艳,等.当归-赤芍配伍对热毒血瘀证模型大鼠的影响[J].中国现代应用药学,2019,36(23):2894-2898.
[15]丁雯,钱大玮,刘培,等.不同提取溶剂对当归赤芍药对主要活性成分溶出率的影响[J].中国中药杂志,2012,37(7):916-919.
[16]刘庆林.赤芍的临床配伍应用浅析[J].光明中医,2009,24(1):131-132.
[17]赵翔凤,相光鑫,王加锋,等.当归功效主治及用药禁忌的本草考证[J].中华中医药杂志,2020,35(5):2479-2482.
[18]王新苗,邸莎,王青,等.赤芍的临床应用及其用量探究[J].吉林中医药,2019,39(8):1017-1020.
[19]王琳琳,丁安伟.赤芍总苷对大鼠血瘀证模型的影响[J].南京中医药大学学报,2011,27(6):552-554.
[20]Dong XY,He ZL,Xiang GH,et al.Paeoniflorin promotes angiogenesis and tissue regeneration in a full-thickness cutaneous wound model through the PI3K/AKT pathway[J].Journal of Cellular Physiology,2020,235(12):9933-9945.
[21]李彦程,王玲燕,李瑞,等.赤芍乙酸乙酯部位化学成分的研究[J].中国中药杂志,2016,41(12):2255-2260.
[22]Wu HX,Chen JY,Wang QT,et al.Expression and function of β-arrestin 2 stimulated by IL-1β in human fibroblast-like synoviocytes and the effect of paeoniflorin[J].International Immunopharmacology,2012,12(4):701-706.
[23]王飞,伍文彬,徐世军,等.赤、白芍对血瘀证动物模型内皮功能及血液流变学的影响[J].中药药理与临床,2009,25(4):40-41.
[24]Fischer SPM,Brusco I,Brum ES,et al.Involvement of TRPV1 and the efficacy ofα-spinasterol on experimental fibromyalgia symptoms in mice[J].Neurochemistry International,2020,134:104673.
[25]Ravikumar YS,Mahadevan KM,Manjunatha H,et al.Antiproliferative,apoptotic and antimutagenic activity of isolated compounds from Polyalthia cerasoides seeds[J].Phytomedicine:International Journal of Phytotherapy and Phytopharmacology,2010,17(7):513-518.
[26]张小琼.裂苞铁苋菜和紫芫花的化学成分与活性研究[D].武汉:华中科技大学,2010.
[27]Pan MH,Lin JH,Lin-Shiau SY,et al.Induction of apoptosis by penta-O-galloyl-β-d-glucose through activation of caspase-3 in human leukemia HL-60 cells[J].European Journal of Pharmacology,1999,381(2/3):171-183.
[28]Ho LL,Chen WJ,Lin-Shiau SY,et al.Penta-O-galloyl-beta-D-glucose inhibits the invasion of mouse melanoma by suppressing metalloproteinase-9 through down-regulation of activator protein-1[J].European Journal of Pharmacology,2002,453(2/3):149-158.
[29]Oh GS,Pae HO,Oh H,et al.In vitro anti-proliferative effect of 1,2,3,4,6-penta-O-galloyl-beta-d-glucose on human hepatocellular carcinoma cell line,SK-HEP-1 cells[J].Cancer Letters,2001,174(1):17-24.
[30]Wang HF,Pang WH,Xu XS,et al.Cryptotanshinone attenuates ischemia/reperfusion-induced apoptosis in myocardium by upregulating MAPK3[J].Journal of Cardiovascular Pharmacology,2021,77(3):370-377.
[31]Hao Y,Yuan HT,Yu HZ.Downregulation of miR-483-5p decreases hypoxia-induced injury in human cardiomyocytes by targeting MAPK3[J].Cellular & Molecular Biology Letters,2020,25:20.
[32]张云,旦菊花,孙鑫,等.MAPKs信号通路在动脉粥样硬化发生发展中的调控作用[J].现代生物医学进展,2017,17(5):968-970.
[33]Lee MY,Luciano AK,Ackah E,et al.Endothelial Akt1 mediates angiogenesis by phosphorylating multiple angiogenic substrates[J].Proceedings of the National Academy of Sciences of the United States of America,2014,111(35):12865-12870.
[34]Lee MY,Gamez-Mendez A,Zhang JS,et al.Endothelial cell autonomous role of Akt1:regulation of vascular tone and ischemia-induced arteriogenesis[J].Arteriosclerosis,Thrombosis,and Vascular Biology,2018,38(4):870-879.
[35]Feng QT,Li X,Qin X,et al.PTEN inhibitor improves vascular remodeling and cardiac function after myocardial infarction through PI3k/Akt/VEGF signaling pathway[J].Molecular Medicine (Cambridge,Mass),2020,26(1):111.
[36]Zhou YH,Han QF,Gao L,et al.HMGB1 protects the heart against ischemia-reperfusion injury via PI3K/AkT pathway-mediated upregulation of VEGF expression[J].Frontiers in Physiology,2019,10:1595.
[37]Quintanilla M,Brown K,Ramsden M,et al.Carcinogen-specificmutation and amplification of Ha-ras during mouse skin carcinogenesis[J].Nature,1986,322(6074):78-80.
[38]Weis SM,Cheresh DA.Pathophysiological consequences of VEGF-induced vascular permeability[J].Nature,2005,437(7058):497-504.
[39]Chen Y,Dawes PT,Packham JC,et al.Interaction between smoking and polymorphism in the promoter region of the VEGFA gene is associated with ischemic heart disease and myocardial infarction in rheumatoid arthritis[J].The Journal of Rheumatology,2011,38(5):802-809.
[40]Huang A,Qi X,Cui YM,et al.Serum VEGF:diagnostic value of acute coronary syndrome from stable angina pectoris and prognostic value of coronary artery disease[J].Cardiology Research and Practice,2020,2020:6786302.

相似文献/References:

[1]程江雪 郭东艳 史亚军邹俊波 张小飞周文晶 李佳奇.不同比例当归赤芍药对配伍对热毒血瘀证模型大鼠的影响[J].陕西中医药大学学报,2021,44(04):100.[doi:10.13424/j.cnki.jsctcm.2021.04.023]

备注/Memo

备注/Memo:
基金项目:陕西中医药大学学科创新团队建设项目(2019-YL11)
更新日期/Last Update: 2022-05-30